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It is estimated that ischaemic heart disease (IHD) will be the
leading contributor to the global burden of disease in the
future, moving from fifth place in 1990 to first in 2020.1
Changes in lifestyle such as increased smoking, sedentary
occupations, adoption of high-fat, high animal protein diets
and increased exposure to stressful urban situations will
increase the risk of IHD and stroke. 2-4 It can be accepted that
cardiovascular disease, already high among whites, coloureds
and Indians, will become a major public health problem among
all South Africans in the future. 
Hypercholesterolaemia is the main risk factor for both IHD
and stroke. It is not surprising that all recent guidelines for
prevention and treatment of cardiovascular disease5-7
emphasise prevention of hypercholesterolaemia through
lifestyle modification and treatment with appropriate lipid-
modifying drugs in high-risk patients. There is no doubt that
the modern  statins and fibrates are effective
hypocholesterolaemic agents and that they reduce
cardiovascular morbidity and mortality. However, the
introduction of these drugs should be approached with care,
considering the expense, possible side-effects and the necessity
for lifetime compliance.5 Behavioural changes are never easy.
The low-fat, high-fibre diet prescribed for prevention and
treatment of hypercholesterolaemia is less palatable than the
typical Western diet. Consequently, worldwide compliance
with this diet has been disappointing.8
It seems, therefore, that there is a need for palatable and
affordable food products that can effectively and safely lower
blood cholesterol levels, reducing risk of IHD and stroke. Such
a food, a spread (margarine) with added plant sterols, has been
developed in Europe and is now available on the South African
market (Pro.active). Plant sterols, b-sitosterol, campesterol and
stigmasterol, are structurally related to cholesterol and usual
dietary intakes vary from 200 mg to 450 mg/day. In larger
quantities, they lower low-density lipoprotein (LDL)
cholesterol by inhibiting exogenous (dietary) and endogenous
(biliary) cholesterol absorption in the intestine. 9 The questions
medical professionals need answered before recommending
this margarine, centre around efficacy, safety, target groups and
affordability.
Efficacy
Extensive clinical testing9-11 involving hundreds of
hypercholesterolaemic subjects has shown that in a dose-
response manner up to 2 g per day of plant sterols
incorporated into food vehicles significantly lowers LDL
cholesterol by approximately 10 - 15% without influencing
high-density lipoprotein (HDL) cholesterol or triglyceride
concentrations. The few studies12 that showed no effect offered
plausible explanations such as giving the sterol in capsules
which prevented mixing of the sterol with gut contents and
consequent absorption of cholesterol, as well as the type of
experimental subjects.12 There is convincing evidence from
randomised clinical trials that plant sterols, when added to a
spread or salad dressing, effectively lower total and LDL
cholesterol in adult hypercholesterolaemic men and women,
independent of their baseline cholesterol levels or background
diet.9-11
Safety issues and target market
The recommended daily portion of the margarine with added
plant sterols provides approximately 10 times more plant
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sterols than normally present in the average Western diet.
Because of possible detrimental effects, the safety of this spread
has been extensively examined in doses of up to 3 g/day for
periods of up to 3 years.13,14 None of these studies found any
evidence that sterol hormone functions, reproductive
characteristics, gut microflora, short-chain fatty acid
production or formation of secondary sterol metabolites were
influenced. There is some concern about a reduced absorption
of lipid-soluble vitamins and pro-vitamins (a - and b -carotenes
and serum lycopenes). Eating more fruit and vegetables should
counter this effect.9 However, there may be some individuals
with a genetic defect resulting in abnormally high absorption
of these plant sterols — sitosterolaemia should be suspected in
a patient who has Achilles tendon as well as cutaneous
xanthomata with normal to severe hypercholesterolaemia in an
autosomal recessive pattern. It is not known if individuals
heterozygous for this condition also absorb higher amounts of
phytosterols. It is advised that homozygous individuals should
not use products with added phytosterols. 15 It is also advised15
that the target market for these products should be adult, non-
pregnant, non-lactating individuals with raised cholesterol
levels or an increased risk of IHD. If the spread is considered
for use in hypercholesterolaemic children, lipid-soluble vitamin
status should be monitored. Before long-term safety studies
have been completed, routine ingestion by the general
population to lower IHD risk is not advised.15 It is
recommended that post-marketing surveillance should be
established to determine the long-term safety of phytosterol
spreads.
Affordability and practical issues
Spreads are used to provide lubrication and taste for the
consumption of bread. Butter contains about 4 g of fat per 5 g
portion, chiefly as saturated fat. Margarines simulate this fat
content but contain plant oils. These may be hydrogenated and
converted to trans-isomers when processed to hard margarines
and are undesirable. The soft margarines have not undergone
these processes and consist mainly of mono- or
polyunsaturated fatty acids. The new spread on the South
African market contains polyunsaturated fatty acids as well as
the plant sterols.
Because of cost and its high water content, the spread should
not be used for baking or frying of foods. It can be expected
that compliance with such a small change in diet, namely
replacing one spread with another, will be better than
compliance with more dramatic dietary interventions. It can be
concluded from the available evidence that this product can be
used to lower total and LDL-cholesterol in
hypercholesterolaemic individuals.
The addition of plant sterols to a spread does not change
taste, consistency or acceptability of the spread. These products
are, however, expensive compared with other spreads, because
2 500 parts of raw material are needed to extract one part of
sterol. But compared with hypolipidaemic drug treatment the
spread with plant sterols may be cost-effective when at-risk
subjects need to lower plasma cholesterol concentration.
Together with a strict lipid-lowering diet, the plant sterol
spread may achieve target concentrations in a significant
number of subjects with moderate hypercholesterolaemia. In
severe hypercholesterolaemia, the LDLcholesterol-lowering
power of the statin drugs is superior, but the combination of a
statin and the spread with added plant sterols displays an
additive effect.9 Where a statin dose has to be doubled to
achieve a LDLcholesterol target concentration, it may therefore
be cost-effective to use the combination of the statin and the
plant sterol-containing spread.
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